Human pluripotent stem cell-derivedβcells:Truly immature isletβcells for type 1 diabetes therapy?  

作　　者：Helen Jiang Fang-Xu Jiang 

机构地区：[1]Sir Charles Gairdner Hospital,University of Western Australia,Perth 6009,Australia [2]School of Biomedical Sciences,University of Western Australia,Perth 6009,Australia [3]School of Health and Medical Sciences,Edith Cowan University,Perth 6027,Australia

出　　处：《World Journal of Stem Cells》2023年第4期182-195,共14页世界干细胞杂志（英文版）（电子版）

基　　金：Supported by the Juvenile Diabetes Research Foundation,No.4-2006-1025;Diabetes Australia Research Trust;Telethon Perth Children’s Hospital Research Fund(TPCHRF)grant to Jiang FX.

摘　　要：A century has passed since the Nobel Prize winning discovery of insulin,which still remains the mainstay treatment for type 1 diabetes mellitus(T1DM)to this day.True to the words of its discoverer Sir Frederick Banting,“insulin is not a cure for diabetes,it is a treatment”,millions of people with T1DM are dependent on daily insulin medications for life.Clinical donor islet transplantation has proven that T1DM is curable,however due to profound shortages of donor islets,it is not a mainstream treatment option for T1DM.Human pluripotent stem cell derived insulin-secreting cells,pervasively known as stem cell-derivedβcells(SC-βcells),are a promising alternative source and have the potential to become a T1DM treatment through cell replacement therapy.Here we briefly review how isletβcells develop and mature in vivo and several types of reported SC-βcells produced using different ex vivo protocols in the last decade.Although some markers of maturation were expressed and glucose stimulated insulin secretion was shown,the SC-βcells have not been directly compared to their in vivo counterparts,generally have limited glucose response,and are not yet fully matured.Due to the presence of extra-pancreatic insulin-expressing cells,and ethical and technological issues,further clarification of the true nature of these SC-βcells is required.

关 键 词：Human pluripotent stem cells Stem cell-derivedβcells Isletβcells Type 1 diabetes mellitus Cell replacement therapy 

分 类 号：R587.1[医药卫生—内分泌]